Tweet
Strongbridge Biopharma plc (NASDAQ:SBBP) shares shot up 6.9% on Thursday . The stock traded as high as $5.60 and last traded at $5.40. 1,625,300 shares were traded during trading, an increase of 281% from the average session volume of 426,044 shares. The stock had previously closed at $5.05.
Several brokerages recently weighed in on SBBP. Cantor Fitzgerald set a $14.00 target price on Strongbridge Biopharma and gave the company a "buy" rating in a research note on Thursday, May 10th. BidaskClub raised Strongbridge Biopharma from a "hold" rating to a "buy" rating in a research note on Saturday, May 5th. ValuEngine raised Strongbridge Biopharma from a "sell" rating to a "hold" rating in a research note on Wednesday, May 2nd. HC Wainwright reaffirmed a "buy" rating on shares of Strongbridge Biopharma in a research note on Friday, May 11th. Finally, Zacks Investment Research cut Strongbridge Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday, May 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Strongbridge Biopharma currently has an average rating of "Hold" and an average target price of $14.75. Get Strongbridge Biopharma alerts:
The company has a market cap of $284.93 million, a price-to-earnings ratio of -3.72 and a beta of 0.60. The company has a quick ratio of 6.38, a current ratio of 6.46 and a debt-to-equity ratio of 8.76. Strongbridge Biopharma (NASDAQ:SBBP) last announced its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.47) by $0.41. Strongbridge Biopharma had a negative return on equity of 1,224.30% and a negative net margin of 624.52%. The business had revenue of $4.30 million during the quarter, compared to analysts' expectations of $4.53 million. sell-side analysts predict that Strongbridge Biopharma plc will post -1.97 earnings per share for the current fiscal year.
In other news, major shareholder Associates L.L.C. Cdk bought 70,000 shares of the firm's stock in a transaction that occurred on Monday, July 30th. The stock was acquired at an average price of $4.66 per share, with a total value of $326,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link . Insiders have purchased 910,795 shares of company stock valued at $4,430,231 in the last ninety days. Company insiders own 4.20% of the company's stock.
A number of hedge funds have recently made changes to their positions in SBBP. Laurion Capital Management LP acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter valued at $101,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter valued at $110,000. Oppenheimer & Co. Inc. acquired a new position in shares of Strongbridge Biopharma in the 1st quarter valued at $119,000. Cubist Systematic Strategies LLC acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter valued at $130,000. Finally, Jane Street Group LLC acquired a new position in shares of Strongbridge Biopharma in the 2nd quarter valued at $154,000. 67.54% of the stock is owned by institutional investors and hedge funds.
About Strongbridge Biopharma ( NASDAQ:SBBP )
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada